Aspheric-based procedures reduce need for re-treatments

Article

Aspheric-based treatments with the SCHWIND ESIRIS excimer laser and ORK-CAM software offer high predictability, increases in visual acuity (VA) and no induction of aberrations.

Aspheric-based treatments with the SCHWIND ESIRIS excimer laser and ORK-CAM software offer high predictability, increases in visual acuity (VA) and no induction of aberrations, according to a recent multicentre study conducted by Maria Clara Arbelaez, MD of the Muscat Eye Laser Center, Muscat, Oman and colleagues from the Charles University, Czech Republic.

The study of 183 eyes utilized the SCHWIND aberration-free treatment, which is designed to leave preoperative higher-order aberrations (HOAs) unchanged allowing patients to retain a habitual sight impression. All flaps were created using the Carriazo-Pendular microkeratome.

In 71% of eyes, the planned refractive result was achieved with a minimum deviation of ±0.25 D. Ninety-one percent were in the area of ±0.5 D and 100% of eyes achieved ±1 D.

Postoperative vision without aids compared with preoperative vision with glasses or contact lenses also increased significantly. At six-months follow-up, 86% of all eyes had achieved an uncorrected visual acuity (UCVA) of 20/20 or better, while only 69% had a best corrected visual acuity (BCVA) of 20/20 or better.

The study also demonstrated that the ORK-CAM software effectively aids the compensation of biomechanical changes of the cornea. At six-months follow-up, no growth of significant aberrations, such as coma or spherical aberration were observed.

It was concluded that the ESIRIS excimer laser and ORK-CAM software can provide good visual results as well as reducing the need for re-treatments.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.